Reversal of endogenous dopamine receptor silencing in pituitary cells augments receptor-mediated apoptosis

Endocrinology

Volumn 152, Issue 2, 2011, Pages 364-373

  Al Azzawi, Haneen ^a   Yacqub Usman, Kiren ^a   Richardson, Alan ^a   Hofland, Leo J ^b   Clayton, Richard N ^a   Farrell, William E ^a  

^a KEELE UNIVERSITY   (United Kingdom)

^b ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

DOPAMINE RECEPTOR; DOPAMINE RECEPTOR STIMULATING AGENT; HISTONE; HISTONE DEACETYLASE INHIBITOR; SMALL INTERFERING RNA; TRICHOSTATIN A; ZEBULARINE;

APOPTOSIS; ARTICLE; CELL LINE; CELL STRAIN GH3; COCULTURE; EPIGENETICS; HUMAN; HYPOPHYSIS CELL; METHYLATION; PRIORITY JOURNAL; PROLACTINOMA; PROTEIN EXPRESSION; TUMOR VOLUME;

ANIMALS; APOPTOSIS; BROMOCRIPTINE; CELL LINE; CHROMATIN IMMUNOPRECIPITATION; DNA METHYLATION; DOPAMINE AGONISTS; DOPAMINE ANTAGONISTS; HALOPERIDOL; HISTONES; PITUITARY GLAND; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, DOPAMINE; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA INTERFERENCE; SALICYLAMIDES;

EID: 79951617680     PISSN: 00137227     EISSN: 00137227     Source Type: Journal    
DOI: 10.1210/en.2010-0886     Document Type: Article

References (45)

1. Ferone D, Pivonello R, Resmini E, Boschetti M, Rebora A, Albertelli M, Albanese V, Colao A, Culler MD, Minuto F 2007 Preclinical and clinical experiences with the role of dopamine receptors in the treatment of pituitary adenomas. Eur J Endocrinol 56(Suppl 1):S37-S43 (Pubitemid 46797842)
2. Hofland LJ, Feelders RA, de Herder WW, Lamberts SW. Pituitary tumours 2010 The sst/D(2) receptors as molecular targets.Mol Cell Endocrinol 326:89-98
3. Colao A, di Sarno A, Pivonello R, di Somma C, Lombardi G 2002 Dopamine receptor agonists for treating prolactinomas. Expert Opin Investig Drugs 11:787-800 (Pubitemid 34618811)
4. Colao A, Pivonello R, Di Somma C, Savastano S, Grasso LF, Lombardi G 2009. Medical therapy of pituitary adenomas: effects on tumor shrinkage Rev Endocr Metab Disord 10:111-123
5. Molitch ME 2005. Pharmacologic resistance in prolactinoma patients. Pituitary 8:43-52 (Pubitemid 44680085)
6. Missale C, Nash SR, Robinson SW, Jaber M, Caron MG 1998. Dopamine receptors: from structure to function. Physiol Rev 78:189-225 (Pubitemid 28070979)
7. Spada A, Nicosia S, Cortelazzi L, Pezzo G, Bassetti M, Sartorio A, Giannattasio G 1983 In vitro studies on prolactin release and adenylate cyclase activity in human prolactin-secreting pituitary adenomas. Different sensitivity of macro- and microadenomas to dopamine and vasoactive intestinal polypeptide. J Clin Endocrinol Metab 56:1-10
8. Ben-Jonathan N 1985. Dopamine: a prolactin-inhibiting hormone. Endocr Rev 6:564-589
9. Picetti R, Saiardi A, Abdel Samad T, Bozzi Y, Baik JH, Borrelli E 1997. Dopamine D2 receptors in signal transduction and behavior. Crit Rev Neurobiol 11:121-142 (Pubitemid 27453167)
10. An JJ, Cho SR, Jeong DW, Park KW, Ahn YS, Baik JH 2003 Antiproliferative effects and cell death mediated by two isoforms of dopamine D2 receptors in pituitary tumor cells. Mol Cell Endocrinol 206:49-62
11. Jaubert A, Ichas F, Bresson-Bepoldin L 2006 Signaling pathway involved in the pro-apoptotic effect of dopamine in the GH3 pituitary cell line. Neuroendocrinology 83:77-88 (Pubitemid 44268154)
12. Rowther FB, Richardson A, Clayton RN, Farrell WE 2010 Bromocriptine and dopamine mediate independent and synergistic apoptotic pathways in pituitary cells. Neuroendocrinology 91:256-267
13. Sharma S, Kelly TK, Jones PA 2010. Epigenetics in cancer. Carcinogenesis 31:27-36
14. Farrell WE 2006 Pituitary tumours: findings from whole genome analyses. Endocr Relat Cancer 13:707-716 (Pubitemid 44763253)
15. Egger G, Liang G, Aparicio A, Jones PA 2004 Epigenetics in human disease and prospects for epigenetic therapy. Nature 429:457-463 (Pubitemid 38715140)
16. Balch C, Montgomery JS, Paik HI, Kim S, Kim S, Huang TH, Nephew KP 2005 New anti-cancer strategies: epigenetic therapies and biomarkers. Front Biosci 10:1897-1931 (Pubitemid 40532955)
17. Pathiraja TN, Stearns V, Oesterreich S 2010 Epigenetic regulation in estrogen receptor positive breast cancer - role in treatment response. J Mammary Gland Biol Neoplasia 15:35-47
18. Martelle JL, Nader MA 2008 A review of the discovery, pharmacological characterization, and behavioral effects of the dopamine D2-like receptor antagonist eticlopride. CNS Neurosci Ther 14:248-262
19. Seeman P, Ulpian C 1988 Dopamine D1 and D2 receptor selectivities of agonists and antagonists. Adv Exp Med Biol 235:55-63
20. Bahar A, Simpson DJ, Cutty SJ, Bicknell JE, Hoban PR, Holley S, Mourtada-Maarabouni M, Williams GT, Clayton RN, Farrell WE 2004 Isolation and characterization of a novel pituitary tumor apoptosis gene. Mol Endocrinol 18:1827-1839 (Pubitemid 38859588)
21. Fink L, Stahl U, Ermert L, Kummer W, Seeger W, Bohle RM 1999 Rat porphobilinogen deaminase gene: a pseudogene-free internal standard for laser-assisted cell picking. Biotechniques 26:510-516
22. Jenuwein T, Allis CD. 2001 Translating the histone code. Science 293:1074-1080 (Pubitemid 32758077)
23. Cao R, Wang L, Wang H, Xia L, Erdjument-Bromage H, Tempst P, Jones RS, Zhang Y 2002 Role of histone H3 lysine 27 methylation in Polycomb-group silencing. Science 298:1039-1043 (Pubitemid 35247314)
24. Roh TY, Cuddapah S, Cui K, Zhao K 2006 The genomic landscape of histone modifications in human T cells. Proc Natl Acad Sci USA 103:15782-15787 (Pubitemid 44657544)
25. Takai D, Jones PA 2003 The CpG island searcher: a new WWW resource. In Silico Biol 3:235-240 (Pubitemid 37493047)
26. Cheng JC, Matsen CB, Gonzales FA, Ye W, Greer S, Marquez VE, Jones PA, Selker EU 2003 Inhibition of DNA methylation and reactivation of silenced genes by zebularine. J Natl Cancer Inst 95:399-409 (Pubitemid 36395260)
27. Garcia-Manero G, Issa JP 2005 Histone deacetylase inhibitors: a review of their clinical status as antineoplastic agents. Cancer Invest 23:635-642 (Pubitemid 43286665)
28. Cameron EE, Bachman KE, Myöhänen S, Herman JG, Baylin SB 1999 Synergy of demethylation and histone deacetylase inhibition in the re-expression of genes silenced in cancer. Nat Genet 21:103-107 (Pubitemid 29036293)
29. Carew JS, Giles FJ, Nawrocki ST 2008 Histone deacetylase inhibitors: mechanisms of cell death and promise in combination cancer therapy. Cancer Lett 269:7-17
30. Dudley KJ, Revill K, Clayton RN, Farrell WE 2009 Pituitary tumours: all silent on the epigenetics front. J Mol Endocrinol 42:461-468
31. Ezzat S 2008 Epigenetic control in pituitary tumors. Endocr J 55:951-957
32. Cheng JC, Yoo CB, Weisenberger DJ, Chuang J, Wozniak C, Liang G, Marquez VE, Greer S, Orntoft TF, Thykjaer T, Jones PA 2004 Preferential response of cancer cells to zebularine. Cancer Cell 6:151-158 (Pubitemid 39485687)
33. Yang X, Ferguson AT, Nass SJ, Phillips DL, Butash KA, Wang SM, Herman JG, Davidson NE 2000 Transcriptional activation of estrogen receptor alpha in human breast cancer cells by histone deacetylase inhibition. Cancer Res 2000 60:6890-6894 (Pubitemid 32059160)
34. Yang X, Phillips DL, Ferguson AT, Nelson WG, Herman JG, Davidson NE 2001 Synergistic activation of functional estrogen receptor (ER)-alpha by DNA methyltransferase and histone deacetylase inhibition in human ER-alpha-negative breast cancer cells. Cancer Res 61:7025-7029 (Pubitemid 32946489)
35. Cheng JC, Weisenberger DJ, Gonzales FA, Liang G, Xu GL, Hu YG, Marquez VE, Jones PA 2004 Continuous zebularine treatment effectively sustains demethylation in human bladder cancer cells. Mol Cell Biol 24:1270-1278 (Pubitemid 38112188)
36. Scott SA, Lakshimikuttysamma A, Sheridan DP, Sanche SE, Geyer CR, DeCoteau JF 2007. Zebularine inhibits human acute myeloid leukemia cell growth in vitro in association with p15INK4B demethylation and reexpression. Exp Hematol 35:263-273 (Pubitemid 46135814)
37. Bondioni S, Angioni AR, Corbetta S, Locatelli M, Ferrero S, Ferrante E, Mantovani G, Olgiati L, Beck-Peccoz P, Spada A, Lania AG 2008 Effect of 9-cis retinoic acid on dopamine D2 receptor expression in pituitary adenoma cells. Exp Biol Med (Maywood) 233:439-446 (Pubitemid 351469300)
38. Martens JH, Brinkman AB, Simmer F, Francoijs KJ, Nebbioso A, Ferrara F, Altucci L, Stunnenberg HG 2010 PML-RARalpha/RXR alters the epigenetic landscape in acute promyelocytic leukemia. Cancer Cell 17:173-185
39. Kristensen LS, Nielsen HM, Hansen LL 2009 Epigenetics and cancer treatment. Eur J Pharmacol 625:131-142
40. Flotho C, Claus R, Batz C, Schneider M, Sandrock I, Ihde S, Plass C, Niemeyer CM, Lübbert M 2009 The DNA methyltransferase inhibitors azacitidine, decitabine and zebularine exert differential effects on cancer gene expression in acute myeloid leukemia cells. Leukemia 23:1019-1028
41. Gius D, Cui H, Bradbury CM, Cook J, Smart DK, Zhao S, Young L, Brandenburg SA, Hu Y, Bisht KS, Ho AS, Mattson D, Sun L, Munson PJ, Chuang EY, Mitchell JB, Feinberg AP 2004 Distinct effects on gene expression of chemical and genetic manipulation of the cancer epigenome revealed by a multimodality approach. Cancer Cell 6:361-371 (Pubitemid 39361437)
42. Gruszka A, Ren SG, Dong J, Culler MD, Melmed S 2007 Regulation of growth hormone and prolactin gene expression and secretion by chimeric somatostatin-dopamine molecules. Endocrinology 148:6107-6114 (Pubitemid 350146153)
43. Tateno T, Kato M, Tani Y, Oyama K, Yamada S, Hirata Y 2009 Differential expression of somatostatin and dopamine receptor subtype genes in adrenocorticotropin (ACTH)-secreting pituitary tumors and silent corticotroph adenomas. Endocr J 56:579-584
44. Neto LV, Machado Ede O, Luque RM, Taboada GF, Marcondes JB, Chimelli LM, Quintella LP, Niemeyer Jr P, de Carvalho DP, Kineman RD, Gadelha MR 2009 Expression analysis of dopamine receptor subtypes in normal human pituitaries, nonfunctioning pituitary adenomas and somatotropinomas, and the association between dopamine and somatostatin receptors with clinical response to octreotide-LAR in acromegaly. J Clin Endocrinol Metab 94:1931-1937
45. Ferguson AT, Lapidus RG, Baylin SB, Davidson NE 1995 Demethylation of the estrogen receptor gene in estrogen receptor-negative breast cancer cells can reactivate estrogen receptor gene expression. Cancer Res 55:2279-2283